Vitra Health

vitrahealth.com

Vitra Health's mission is to create a safe and caring environment for all of our clients. We do this by bringing the human connection back to home health care. We understand that every client is unique, and we bring an individualized approach to improving your service.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

NANOBIOTIX ANNOUNCES LICENSE AGREEMENT FOR WORLDWIDE CO-DEVELOPMENT AND COMMERCIALIZATION OF POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3

Globenewswire | July 13, 2023

news image

NANOBIOTIX a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. NBTXR3 is currently being evaluated in several studies across solid tumor in...

Read More

Industrial Impact

BIOCYTOGEN AND LIBEROTHERA ACHIEVE MILESTONE PROGRESS IN CO-DEVELOPMENT OF FULLY HUMAN GPCR ANTIBODY DRUGS

Biocytogen | July 21, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. entered a strategic collaboration with LiberoThera Co., Ltd to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excellent anti-tumo...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

Industrial Impact

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More
news image

Medical, Industry Outlook

NANOBIOTIX ANNOUNCES LICENSE AGREEMENT FOR WORLDWIDE CO-DEVELOPMENT AND COMMERCIALIZATION OF POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3

Globenewswire | July 13, 2023

NANOBIOTIX a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. NBTXR3 is currently being evaluated in several studies across solid tumor in...

Read More
news image

Industrial Impact

BIOCYTOGEN AND LIBEROTHERA ACHIEVE MILESTONE PROGRESS IN CO-DEVELOPMENT OF FULLY HUMAN GPCR ANTIBODY DRUGS

Biocytogen | July 21, 2022

Biocytogen Pharmaceuticals Co., Ltd. entered a strategic collaboration with LiberoThera Co., Ltd to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excellent anti-tumo...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More